Evogene Ltd. filed a Form 6-K with the U.S. Securities and Exchange Commission on November 16, 2026, disclosing the resignation of Nir Nimrodi as chairman and member of the board of directors, effective November 13, 2026.

Key Highlights

  • Resignation date: Nir Nimrodi notified the board of his resignation on November 13, 2026.
  • Role vacated: Nimrodi held the position of chairman and member of the board of directors.
  • No disagreement: According to the filing, Nimrodi's resignation "was not related to any disagreement with the Company on any matter relating to its operations, policies or practices."
  • Signed by CEO: The report was signed by Ofer Haviv, Chief Executive Officer, on November 16, 2026.
  • Incorporated by reference: The filing is incorporated by reference into the company's registration statements on Form F-3 and Form S-8 filed with the SEC.

Evogene Board Chairman Steps Down in November 2026

Evogene Ltd. (NASDAQ:EVGN), an Israeli bioinformatics company headquartered at 13 Gad Feinstein Street, Park Rehovot, Israel, reported that Nir Nimrodi notified its board of directors of his resignation on November 13, 2026. Nimrodi served as both a member and chairman of the board, and the filing confirms he vacated both roles simultaneously.

The company disclosed that the departure was not tied to any dispute with Evogene. The filing states verbatim that Nimrodi's resignation "was not related to any disagreement with the Company on any matter relating to its operations, policies or practices." No successor chairman or interim appointment was named in the filing.

The Form 6-K, submitted for the month of November 2026 under Commission File Number 001-36187, was signed by Chief Executive Officer Ofer Haviv. The company noted that the contents of the report are incorporated by reference into its registration statements on Form F-3 (SEC File Nos. 333-277565 and 333-294650) and Form S-8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, 333-286197, and 333-294648), to the extent not superseded by subsequently filed documents.

What Was Disclosed

Evogene Ltd. disclosed through a Form 6-K that board chairman Nir Nimrodi resigned his position as chairman and board member on November 13, 2026, with the company stating the resignation was unrelated to any disagreement over its operations, policies, or practices.